{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:12:33Z","timestamp":1785265953881,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["20224Y0162"],"award-info":[{"award-number":["20224Y0162"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89272-x","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T16:02:28Z","timestamp":1739030548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Bu-kun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"24","key":"89272_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","volume":"28","author":"CK Tan","year":"2022","unstructured":"Tan, C. K., Ho, D., Wang, L. M. & Kumar, R. Drug-induced autoimmune hepatitis: A minireview. World J. Gastroenterol. 28(24), 2654\u20132666 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"89272_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jhep.2011.02.024","volume":"55","author":"C Weiler-Normann","year":"2011","unstructured":"Weiler-Normann, C. & Schramm, C. Drug induced liver injury and its relationship to autoimmune hepatitis. J. Hepatol. 55(4), 747\u2013749 (2011).","journal-title":"J. Hepatol."},{"issue":"3","key":"89272_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","volume":"79","author":"RJ Andrade","year":"2023","unstructured":"Andrade, R. J. et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J. Hepatol. 79(3), 853\u2013866 (2023).","journal-title":"J. Hepatol."},{"issue":"2","key":"89272_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack, C. L. et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 72(2), 671\u2013722 (2020).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4","key":"89272_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J. Hepatol. 63(4), 971\u20131004 (2015).","journal-title":"J. Hepatol."},{"issue":"9","key":"89272_CR6","first-page":"1686","volume":"38","author":"V Gordon","year":"2018","unstructured":"Gordon, V. et al. Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK. Liver Int. Off. J. Int. Assoc. Study Liver 38(9), 1686\u20131695 (2018).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"6","key":"89272_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bj\u00f6rnsson","year":"2010","unstructured":"Bj\u00f6rnsson, E. et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology (Baltimore, Md) 51(6), 2040\u20132048 (2010).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"12","key":"89272_CR8","first-page":"2341","volume":"39","author":"KB Valgeirsson","year":"2019","unstructured":"Valgeirsson, K. B., Hreinsson, J. P. & Bj\u00f6rnsson, E. S. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int. Off. J. Int. Assoc. Study Liver 39(12), 2341\u20132349 (2019).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"1","key":"89272_CR9","first-page":"103","volume":"15","author":"YS de Boer","year":"2017","unstructured":"de Boer, Y. S. et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 15(1), 103-112.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"12","key":"89272_CR10","first-page":"1116","volume":"46","author":"A Licata","year":"2014","unstructured":"Licata, A. et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 46(12), 1116\u20131120 (2014).","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"issue":"6","key":"89272_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Therapeutics 89(6), 806\u2013815 (2011).","journal-title":"Clin. Pharmacol. Therapeutics"},{"issue":"1","key":"89272_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cld.2019.09.007","volume":"24","author":"L Meurer","year":"2020","unstructured":"Meurer, L. & Cohen, S. M. Drug-induced liver injury from statins. Clin. Liver Dis. 24(1), 107\u2013119 (2020).","journal-title":"Clin. Liver Dis."},{"issue":"4","key":"89272_CR13","first-page":"246","volume":"106","author":"EV Perdices","year":"2014","unstructured":"Perdices, E. V. et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev. espanola de enfermedades digestivas 106(4), 246\u2013254 (2014).","journal-title":"Rev. espanola de enfermedades digestivas"},{"issue":"10","key":"89272_CR14","first-page":"1906","volume":"39","author":"S Weber","year":"2019","unstructured":"Weber, S., Benesic, A., Rotter, I. & Gerbes, A. L. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int. Off. J. Int. Assoc. Study Liver 39(10), 1906\u20131917 (2019).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"10","key":"89272_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/apt.13159","volume":"41","author":"E Shelton","year":"2015","unstructured":"Shelton, E. et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment. Pharmacol. Therapeutics 41(10), 972\u2013979 (2015).","journal-title":"Aliment. Pharmacol. Therapeutics"},{"key":"89272_CR16","doi-asserted-by":"publisher","first-page":"1044744","DOI":"10.3389\/fphar.2022.1044744","volume":"13","author":"S Zhou","year":"2022","unstructured":"Zhou, S. et al. Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database. Front. Pharmacol. 13, 1044744 (2022).","journal-title":"Front. Pharmacol."},{"key":"89272_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","volume":"139","author":"C Khouri","year":"2021","unstructured":"Khouri, C. et al. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J. Clin. Epidemiol. 139, 191\u2013198 (2021).","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"89272_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate, A. Bayesian confidence propagation neural network. Drug Saf. 30(7), 623\u2013625 (2007).","journal-title":"Drug Saf."},{"issue":"6","key":"89272_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/pds.2247","volume":"21","author":"C Berlin","year":"2012","unstructured":"Berlin, C. et al. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. Pharmacoepidemiol. Drug Saf. 21(6), 622\u2013630 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"89272_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3350\/cmh.2020.0189","volume":"27","author":"A Komori","year":"2021","unstructured":"Komori, A. Recent updates on the management of autoimmune hepatitis. Clin. Mol. Hepatol. 27(1), 58\u201369 (2021).","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"89272_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0049-0172(98)80035-8","volume":"28","author":"JM Angulo","year":"1998","unstructured":"Angulo, J. M., Sigal, L. H. & Espinoza, L. R. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin. Arthritis Rheum. 28(3), 187\u2013192 (1998).","journal-title":"Semin. Arthritis Rheum."},{"issue":"11","key":"89272_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archpedi.152.11.1132","volume":"152","author":"JE Teitelbaum","year":"1998","unstructured":"Teitelbaum, J. E. et al. Minocycline-related autoimmune hepatitis: Case series and literature review. Arch. Pediatr. Adolesc. Med. 152(11), 1132\u20131136 (1998).","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"3","key":"89272_CR23","volume":"14","author":"O Rafa","year":"2022","unstructured":"Rafa, O., Basile, E. J., Frankini, E. & Ahmed, A. Rapid development of autoimmune hepatitis secondary to minocycline. Cureus 14(3), e23038 (2022).","journal-title":"Cureus"},{"issue":"4","key":"89272_CR24","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/hep.31029","volume":"71","author":"A Fakhreddine","year":"2020","unstructured":"Fakhreddine, A. & Frenette, C. A cautionary report of doxycycline-induced autoimmune hepatitis. Hepatology (Baltimore, Md) 71(4), 1515\u20131517 (2020).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"8","key":"89272_CR25","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000440","volume":"7","author":"JJ Pan","year":"2020","unstructured":"Pan, J. J. & Promrat, K. Doxycycline-induced autoimmune hepatitis. ACG Case Rep. J. 7(8), e00440 (2020).","journal-title":"ACG Case Rep. J."},{"issue":"5","key":"89272_CR26","volume":"14","author":"R Liang","year":"2022","unstructured":"Liang, R. & Ramdass, A. Azithromycin-induced liver injury in an asthma exacerbation patient with autoimmune features. Cureus 14(5), e25447 (2022).","journal-title":"Cureus"},{"issue":"5","key":"89272_CR27","first-page":"819","volume":"93","author":"BD Kelly","year":"1998","unstructured":"Kelly, B. D. et al. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am. J. Gastroenterol. 93(5), 819\u2013821 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"89272_CR28","doi-asserted-by":"crossref","unstructured":"Hoofnagle, J. H. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (National Institute of Diabetes and Digestive and Kidney Diseases, 2012).","DOI":"10.1016\/B978-0-12-387817-5.00040-6"},{"issue":"5","key":"89272_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/1319-3767.84494","volume":"17","author":"GV Trikudanathan","year":"2011","unstructured":"Trikudanathan, G. V., Ahmad, I. & Israel, J. L. Concurrent autoimmune hepatitis and grave\u2019s disease in hepatitis C during pegylated interferon \u03b1-2a and ribavirin therapy. Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc. 17(5), 348\u2013352 (2011).","journal-title":"Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc."},{"issue":"2","key":"89272_CR30","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.transproceed.2012.02.049","volume":"45","author":"XY Zhao","year":"2013","unstructured":"Zhao, X. Y., Rakhda, M. I., Wang, T. I. & Jia, J. D. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: A case report with literature review. Transpl. Proc. 45(2), 824\u2013827 (2013).","journal-title":"Transpl. Proc."},{"issue":"12","key":"89272_CR31","first-page":"xx","volume":"2","author":"J L\u00f6rke","year":"2004","unstructured":"L\u00f6rke, J., Erhardt, A. & H\u00e4ussinger, D. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin. Gastroenterol. Hepatol. Off. Clin. Prac. J. Am. Gastroenterol. Assoc. 2(12), xx (2004).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Prac. J. Am. Gastroenterol. Assoc."},{"issue":"2","key":"89272_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.27157","volume":"60","author":"MW Russo","year":"2014","unstructured":"Russo, M. W. et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology (Baltimore, Md.) 60(2), 679\u2013686 (2014).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"10","key":"89272_CR33","volume":"15","author":"J Tse","year":"2023","unstructured":"Tse, J., Natla, S., Mekala, R., Crumm, I. & Olken, M. H. Atorvastatin-induced autoimmune hepatitis: A case report. Cureus 15(10), e47807 (2023).","journal-title":"Cureus"},{"issue":"3","key":"89272_CR34","volume":"12","author":"AA Khan","year":"2020","unstructured":"Khan, A. A., Ahmed, S., Mohammed, A. & Elzouki, A. Y. Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review. Cureus 12(3), e7299 (2020).","journal-title":"Cureus"},{"issue":"3","key":"89272_CR35","volume":"16","author":"M Patel","year":"2024","unstructured":"Patel, M., Fattah, A., Hussaini, H., Maneesha, F. & Ahmed, Z. Drug-induced autoimmune hepatitis: An unusual adverse event of atorvastatin therapy. Cureus 16(3), e55809 (2024).","journal-title":"Cureus"},{"issue":"8","key":"89272_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","volume":"40","author":"V Alla","year":"2006","unstructured":"Alla, V. et al. Autoimmune hepatitis triggered by statins. J. Clin. Gastroenterol. 40(8), 757\u2013761 (2006).","journal-title":"J. Clin. Gastroenterol."},{"issue":"5","key":"89272_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/00042737-200505000-00019","volume":"17","author":"LM Wolters","year":"2005","unstructured":"Wolters, L. M. & Van Buuren, H. R. Rosuvastatin-associated hepatitis with autoimmune features. Eur. J. Gastroenterol. Hepatol. 17(5), 589\u2013590 (2005).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"9","key":"89272_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.medcli.2014.11.017","volume":"145","author":"M Alvarado C\u00e1rdenas","year":"2015","unstructured":"Alvarado C\u00e1rdenas, M. et al. Estatinas y autoinmunidad [Statins and autoimmunity]. Medicina Clinica 145(9), 399\u2013403 (2015).","journal-title":"Medicina Clinica"},{"issue":"6","key":"89272_CR39","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/hep.29228","volume":"66","author":"S Barge","year":"2017","unstructured":"Barge, S., Ziol, M. & Nault, J. C. Autoimmune-like chronic hepatitis induced by olmesartan. Hepatology (Baltimore, Md.) 66(6), 2086\u20132088 (2017).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"10","key":"89272_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.gastrohep.2020.03.018","volume":"43","author":"D Riado Minguez","year":"2020","unstructured":"Riado Minguez, D., Gutierrez Garcia, M. L. & Fernandez Rodriguez, C. Chronic autoimmune hepatitis triggered by olmesartan. Gastroenterologia y Hepatologia 43(10), 629\u2013630 (2020).","journal-title":"Gastroenterologia y Hepatologia"},{"issue":"3","key":"89272_CR41","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1097\/MJT.0000000000000983","volume":"27","author":"T Syed","year":"2020","unstructured":"Syed, T. et al. Nivolumab-induced delayed autoimmune hepatitis-A diagnostic and therapeutic challenge. Am. J. Therapeutics 27(3), e317\u2013e319 (2020).","journal-title":"Am. J. Therapeutics"},{"issue":"6","key":"89272_CR42","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen, Y. & Yeh, M. M. Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc 31(6), 965\u2013973 (2018).","journal-title":"Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc"},{"issue":"11","key":"89272_CR43","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long, G. V. et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): Distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 23(11), 1378\u20131388 (2022).","journal-title":"Lancet Oncol."},{"issue":"Pt A","key":"89272_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111158","volume":"125","author":"Z Liu","year":"2023","unstructured":"Liu, Z., Bao, Z., Yu, B., Chen, L. & Yang, G. Pemetrexed ameliorates Con A-induced hepatic injury by restricting M1 macrophage activation. Int. Immunopharmacol. 125(Pt A), 111158 (2023).","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"89272_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.msard.2013.09.008","volume":"3","author":"E Sinagra","year":"2014","unstructured":"Sinagra, E. et al. Does glatiramer acetate provoke hepatitis in multiple sclerosis?. Mult. Scler. Relat. Disord. 3(2), 266\u2013268 (2014).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"89272_CR46","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00415-006-0441-3","volume":"254","author":"H Neumann","year":"2007","unstructured":"Neumann, H., Csepregi, A., Sailer, M. & Malfertheiner, P. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. J. Neurol. 254(6), 816\u2013817 (2007).","journal-title":"J. Neurol."},{"issue":"8","key":"89272_CR47","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1111\/j.1572-0241.2008.01982_9.x","volume":"103","author":"V von Kalckreuth","year":"2008","unstructured":"von Kalckreuth, V., Lohse, A. W. & Schramm, C. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis\u2013not only beta interferon. Am. J. Gastroenterol. 103(8), 2147\u20132148 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"89272_CR48","doi-asserted-by":"crossref","unstructured":"Deltenre, P., Peny, M. O., Dufour, A., Nady, M. E., & Henrion, J. Acute hepatitis induced by glatiramer acetate. BMJ Case Reports. 2009, bcr09.2008.0913 (2009).","DOI":"10.1136\/bcr.09.2008.0913"},{"issue":"2","key":"89272_CR49","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2174\/157488612802715690","volume":"7","author":"K Subramaniam","year":"2012","unstructured":"Subramaniam, K., Pavli, P., Llewellyn, H. & Chitturi, S. Glatiramer acetate induced hepatotoxicity. Curr. Drug Saf. 7(2), 186\u2013188 (2012).","journal-title":"Curr. Drug Saf."},{"issue":"4","key":"89272_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.gastrohep.2014.06.001","volume":"38","author":"N Fern\u00e1ndez Fern\u00e1ndez","year":"2015","unstructured":"Fern\u00e1ndez Fern\u00e1ndez, N. et al. Hepatitis asociada a acetato de glatir\u00e1mero [Hepatitis induced by glatiramer acetate]. Gastroenterologia y Hepatologia 38(4), 280\u2013281 (2015).","journal-title":"Gastroenterologia y Hepatologia"},{"issue":"11","key":"89272_CR51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1756285617722352","volume":"10","author":"J Almeida","year":"2017","unstructured":"Almeida, J. et al. Liver injury and glatiramer acetate, an uncommon association: Case report and literature review. Therapeutic Adv. Neurol. Disord. 10(11), 367\u2013372 (2017).","journal-title":"Therapeutic Adv. Neurol. Disord."},{"issue":"8","key":"89272_CR52","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","volume":"35","author":"M Biolato","year":"2021","unstructured":"Biolato, M. et al. The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: A narrative review. CNS Drugs 35(8), 861\u2013880 (2021).","journal-title":"CNS Drugs"},{"issue":"9","key":"89272_CR53","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1212\/WNL.0b013e3182a2cc4a","volume":"81","author":"N Makhani","year":"2013","unstructured":"Makhani, N., Ngan, B. Y., Kamath, B. M. & Yeh, E. A. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology 81(9), 850\u2013852 (2013).","journal-title":"Neurology"},{"issue":"6","key":"89272_CR54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1352458520913277","volume":"26","author":"HP Hartung","year":"2020","unstructured":"Hartung, H. P., Mares, J. & Barnett, M. H. Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Mult. Sclerosis (Houndmills, Basingstoke, England). 26(6), 737\u2013740 (2020).","journal-title":"Mult. Sclerosis (Houndmills, Basingstoke, England)."},{"issue":"9","key":"89272_CR55","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458515614092","volume":"22","author":"MD Willis","year":"2016","unstructured":"Willis, M. D. et al. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult. Sclerosis (Houndmills, Basingstoke, England). 22(9), 1215\u20131223 (2016).","journal-title":"Mult. Sclerosis (Houndmills, Basingstoke, England)."},{"issue":"2","key":"89272_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13760-018-0922-z","volume":"118","author":"S El Sankari","year":"2018","unstructured":"El Sankari, S., Dahlqvist, G., Monino, L. & van Pesch, V. Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab. Acta Neurol. Belgica 118(2), 331\u2013333 (2018).","journal-title":"Acta Neurol. Belgica"},{"issue":"1","key":"89272_CR57","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/hep.31435","volume":"73","author":"FJ Bolte","year":"2021","unstructured":"Bolte, F. J., Schmidt, H. H. & Schlevogt, B. Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with multiple sclerosis. Hepatology (Baltimore, Md.) 73(1), 460\u2013463 (2021).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"1","key":"89272_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","volume":"12","author":"T Holm\u00f8y","year":"2019","unstructured":"Holm\u00f8y, T., Fevang, B., Olsen, D. B., Spigset, O. & B\u00f8, L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res. Notes 12(1), 497 (2019).","journal-title":"BMC Res. Notes"},{"issue":"8","key":"89272_CR59","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker, D. et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol. 74(8), 961\u2013969 (2017).","journal-title":"JAMA Neurol."},{"issue":"4","key":"89272_CR60","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s10620-009-0805-5","volume":"55","author":"P Mart\u00ednez-Odriozola","year":"2010","unstructured":"Mart\u00ednez-Odriozola, P. et al. Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig. Dis. Sci. 55(4), 1191\u20131192 (2010).","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"89272_CR61","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/BF01316809","volume":"38","author":"LJ Scully","year":"1993","unstructured":"Scully, L. J., Clarke, D. & Barr, R. J. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig. Dis. Sci. 38(4), 744\u2013751 (1993).","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"89272_CR62","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2169\/internalmedicine.53.1362","volume":"53","author":"A Naito","year":"2014","unstructured":"Naito, A. et al. Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists. Intern. Med. (Tokyo, Japan) 53(7), 771\u2013775 (2014).","journal-title":"Intern. Med. (Tokyo, Japan)"},{"issue":"1","key":"89272_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15403\/jgld.2014.1121.271.ajo","volume":"27","author":"A de Araujo","year":"2018","unstructured":"de Araujo, A. et al. Bosentan inducing autoimmune hepatitis in a patient with idiopathic pulmonary arterial hypertension. J. Gastrointest. Liver Dis. JGLD 27(1), 89\u201392 (2018).","journal-title":"J. Gastrointest. Liver Dis. JGLD"},{"issue":"3","key":"89272_CR64","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001003","volume":"10","author":"Y Hegazy","year":"2023","unstructured":"Hegazy, Y., Axley, P., Lee, G. & Gray, M. Levetiracetam liver injury: A benign antiepileptic agent?. ACG Case Rep. J. 10(3), e01003 (2023).","journal-title":"ACG Case Rep. J."},{"issue":"7","key":"89272_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29792","volume":"96","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967\u20132023: A comprehensive analysis of the international pharmacovigilance database. J. Med. Virol. 96(7), e29792 (2024).","journal-title":"J. Med. Virol."},{"issue":"2","key":"89272_CR66","first-page":"80","volume":"11","author":"H Zhou","year":"2023","unstructured":"Zhou, H. & Ye, Q. Clinical features of COVID-19 vaccine-associated autoimmune hepatitis: A systematic review. Diseases (Basel, Switzerland) 11(2), 80 (2023).","journal-title":"Diseases (Basel, Switzerland)"},{"issue":"3","key":"89272_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101489","volume":"29","author":"A Barreira-D\u00edaz","year":"2024","unstructured":"Barreira-D\u00edaz, A. et al. Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study. Ann. Hepatol. 29(3), 101489 (2024).","journal-title":"Ann. Hepatol."},{"issue":"6","key":"89272_CR68","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cmi.2017.151","volume":"15","author":"Y Segal","year":"2018","unstructured":"Segal, Y. & Shoenfeld, Y. Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction. Cell Mol. Immunol. 15(6), 586\u2013594 (2018).","journal-title":"Cell Mol. Immunol."},{"issue":"6","key":"89272_CR69","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bj\u00f6rnsson","year":"2010","unstructured":"Bj\u00f6rnsson, E. et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology 51(6), 2040\u20132048 (2010).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89272-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T16:49:32Z","timestamp":1739033372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89272-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89272"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89272-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since the FAERS database is publicly accessible and contains anonymized and de-identified patient records, this study does not require informed consent or ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"4783"}}